News

2023.01.04Remiges Portfolio Companies Raised In Aggregate More Than $145 million in 2022

2022.12.23Immunohelix Co., Ltd, one of our portfolio companies, was selected for AMED Strengthening Program for Pharmaceutical Venture Ecosystem

2022.09.26Remiges Ventures led the Series A round of finance for Kupando GmbH in Germany

2022.06.30Remiges selected as Certified VC by the AMED Strengthening Program for Pharmaceutical Venture Ecosystem

2022.06.06Luca Science, one of our portfolio companies in Japan, closed a $30.3M Series B round

2022.06.02Tranquis Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of TQS-168

2022.03.08Digestome Therapeutics announced first patient enrolled in Phase 1 clinical trial of DGX-001

2022.02.04Remiges Ventures co-led the Series Seed round of finance for Restore Vision, Inc. in Japan

2022.01.10Inflects Bioscience receives approval from French regulatory authority to conduct a Phase 2 Clinical Trial for IFB-088 for ALS

2021.06.23Remiges joined Series B Round of Glycomine in California

2021.05.27The core technology of Imel BioTherapeutics, Inc. was published in Scientific Reports

2021.04.09Remiges Ventures Closes Second Fund with $95 million; Launches RDiscovery Incubator

2020.12.10Remiges led the Series A round of finance for Cyrano Therapeutics in Washington D.C.

2020.07.09
Remiges co-led the Series A round of finance for Tranquis Therapeutics in California

2020.04.20
Remiges led the Series A round of finance for Phost'In Therapeutics in France

2020.03.01
Remiges Welcomes New Team Member

2020.01.07
Inflectis BioScience announced successful completion of Phase 1 clinical trial of IFB-088

2020.01.01
Remiges Welcomes New Team Member

2019.04.01
Remiges created our third seed stage company based on intellectual properties from the Japanese academia

2019.04.01
Remiges created our second seed stage company based on intellectual properties from the Japanese academia

2019.02.04
ENB Therapeutics one of the Remiges Ventures' portfolio companies announced its clinical trial collaboration with Merck

2018.11.02
OMEICOS Therapeutics one of the Remiges Ventures' portfolio companies closed its €17m Series C financing

2018.09.21
Remiges led the Series A round of finance for ENB Therapeutics in New York

2018.06.27
Remiges created a de novo company based on intellectual properties from a national university in Japan

2018.06.13
Remiges joined Series A1 Round of KisoJi Biotechnology in Montreal Canada

2017.10.04
Remiges joined Extension of Series B Round of Omeicos Therapeutics to expand its technology into Ophthalmology

2017.06.27
Remiges led the Series A round of finance for Mitoconix Bio in Israel

2017.03.06
Remiges Welcomes New Partner

2017.02.14
The final closing of Remiges BioPharma Fund achieved raising a total $80 million

2016.06.01
Remiges co-led the Series A round of finance for InFlectis BioScience in France

2016.04.19
Remiges selected as Certified VC by the NEDO Technology-based Startup Support Program